You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells
|
|---|---|
| Published in |
Frontiers in Pharmacology, May 2017
|
| DOI | 10.3389/fphar.2017.00270 |
| Pubmed ID | |
| Authors |
Dhaval S. Sanchala, Lokesh K. Bhatt, Kedar S. Prabhavalkar |
| Abstract |
Oncolytic viral therapy, which makes use of replication-competent lytic viruses, has emerged as a promising modality to treat malignancies. It has shown meaningful outcomes in both solid tumor and hematologic malignancies. Advancements during the last decade, mainly genetic engineering of oncolytic viruses have resulted in improved specificity and efficacy of oncolytic viruses in cancer therapeutics. Oncolytic viral therapy for treating cancer with herpes simplex virus-1 has been of particular interest owing to its range of benefits like: (a) large genome and power to infiltrate in the tumor, (b) easy access to manipulation with the flexibility to insert multiple transgenes, (c) infecting majority of the malignant cell types with quick replication in the infected cells and (d) as Anti-HSV agent to terminate HSV replication. This review provides an exhaustive list of oncolytic herpes simplex virus-1 along with their genetic alterations. It also encompasses the major developments in oncolytic herpes simplex-1 viral therapy and outlines the limitations and drawbacks of oncolytic herpes simplex viral therapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Argentina | 1 | 50% |
| Switzerland | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 77 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 16 | 21% |
| Student > Ph. D. Student | 12 | 16% |
| Researcher | 10 | 13% |
| Student > Doctoral Student | 7 | 9% |
| Student > Master | 7 | 9% |
| Other | 8 | 10% |
| Unknown | 17 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 23 | 30% |
| Immunology and Microbiology | 9 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Medicine and Dentistry | 6 | 8% |
| Agricultural and Biological Sciences | 5 | 6% |
| Other | 9 | 12% |
| Unknown | 19 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 July 2022.
All research outputs
#6,788,263
of 22,792,160 outputs
Outputs from Frontiers in Pharmacology
#2,735
of 16,015 outputs
Outputs of similar age
#107,164
of 309,940 outputs
Outputs of similar age from Frontiers in Pharmacology
#57
of 252 outputs
Altmetric has tracked 22,792,160 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 16,015 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 309,940 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 252 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.